|
Study | N | Duration | In/out, patient | Design | Antipsychotic dose | Dropouts Relapse | Dropouts Side effects | Comments |
|
Zuardi et al. [47] | 22 | 16 weeks | In | RDM DB | HAL DEC 20 mg IM/4 w : 1 mg/d PO* | ND | ND | LAI = marginally better efficacy and more EPS |
Kinross-Wright and Charalampous [48] | 40 | 6 weeks | In | RDM DB | FLZ ETH# 25 mg IM/2 w versus 2.5–7.5 mg PO | ND | ND | — |
Ravaris et al. [49] | 39 | 24 weeks | In | RDM DB | FLZ ETH 12–25 mg IM/2 w versus 2.5–10 mg PO | 5% (LAI) 0% (PO) | 5% (LAI) 6% (PO) | — |
Haider [50] | 43 | 6 weeks | In | RDM DB | FLZ ETH 25 mg IM/2-3 w versus 2.5–10 mg/d PO | ND | ND | LAI = more EPS |
van Praag et al. [51] | 50 | 4 weeks | In | RDM DB | FLZ ETH# 25 mg IM/3 w versus 7 mg/d PO | ND | ND | LAI = more EPS |
Del Giudice et al. [52] | 88 | 15 months | Out | RDM SBP | FLZ ETH# 25 mg IM/2 w versus 22 mg/d PO | ND | ND | LAI = longer time to relapse and more EPS |
Rifkin et al. [53] | 73 | 12 months | Out | RDM DB | FLZ DEC 12.5 mg IM/2 w: 5 mg/d PO+ | 4% (LAI) 7% (PO) | 22% (LAI) 4% (PO) | LAI = more EPS |
Hogarty et al. [54] | 105 | 24 months | Out | RDM DB | FLZ DEC 34–43 mg IM/2 w versus 10–12 mg/d PO | 23% (LAI+ST) 50% (LAI) 55% (PO) 66% (PO+ST) | 9% (LAI) 0% (PO) | LAI = more anxiety/depression, but less positive symptoms |
Schooler et al. [55] | 214 | 12 months | Out | RDM DB | FLZ DEC# 34 mg IM/3 w versus 25 mg/d PO | 24% (LAI) 33% (PO) | 5% (LAI) 4% (PO) | — |
Arango et al. [56] | 46 | 12 months | Out | RDM OL | ZUC DEC# 233 mg IM/2 w versus 35 mg/d PO | 4% (LAI) 5% (PO) | ND | LAI = less violence |
Chue et al. [26] | 541 | 3 months | Both | RDM DB | RIS MIC 25–75 mg IM/2 w versus 2–6 mg/d PO | 4% (LAI) 3% (PO) | 6% (LAI) 5% (PO) | LAI = less prolactin elevation |
Bai et al. [57] | 50 | 12 months | In | RDM SBI | RIS MIC 25–50 mg IM/2 w versus 4–6 mg/d PO | 8% (LAI) 0% (PO) | 4% (LAI) 0% (PO) | LAI = lower UKU score, lower EPS and prolactin levels |
Eli Lily [58] | 524 | 24 months | Out | RDM OL | OLZ PAM 150–405 mg IM/4 w versus 5–20 mg/d PO | 16% (LAI) 10% (PO) | 10% (LAI) 10% (PO) | LAI = less rehospitalisations |
Kane et al. [25] | 1065 | 6 months | Out | RDM DB | OLZ PAM 45 mg IM/4 w versus 150 mg IM/2 w versus 405 mg IM/4 w versus 300 mg IM/2 w versus 10, 15, 20 mg/d PO | 6% (LAIHI) 13% (LAIMD) 19% (LAILO) 8% (PO) | 3% (LAIHI) 3% (LAIMD) 5% (LAILO) 3% (PO) | — |
Kim et al. [60] | 50 | 24 months | Out | NAT (FEP) | RIS MIC# 29 mg/2 w versus 3 mg/d PO | 23% (LAI) 75% (PO) | ND | LAI = lower relapse rate |
Zhu et al. [59] | 299 | 12 months | Out | NAT | HAL DEC# 100 mg/4 w versus 11 mg/d PO FLZ DEC# 25 mg/2 w versus 12 mg/d PO | ND | ND | LAI = longer time to discontinuation |
Tiihonen et al. [61] | 2230 | 3.6 years# | Out | NAT (FEP) | PER DEC versus oral equivalent | ND | ND | LAI = lower risk of rehospitalization |
Tiihonen et al. [9] | 2588 | 24 months | Out | NAT (FEP) | RIS MIC, HAL DEC, PER DEC, ZUC DEC versus oral equivalent | ND | ND | LAI = lower risk of rehospitalization |
|